Menu
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
The medical technology company, which makes a portable dialysis machine, delivered its fourth-quarter and full-year report on Monday.
Benzinga Pro data, Outset Medical (NASDAQ: OM ) reported Q4 sales of $32.01 million. Earnings fell to a loss of $41.44 million, resulting in a 1.63% decrease from last quarter. Outset Medical collected $27.76 million in revenue during Q3, but reported earnings showed a $40.78 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a … Full story available on Benzinga.com
https://www.investing.com/news/pro/rbc-capital-remains-positive-on-outset-medical-inc-432SI-3003003
Soligenix SNGX -40% as FDA declines to review photodynamic therapy for cancer.Energy Services of America ESOA -26% on Q1 earnings release.T2 Biosystems TTOO -16% on…
Outset Medical, Inc. (NASDAQ:NASDAQ:OM) Q4 2022 Earnings Conference Call February 13, 2023 5:00 PM ETCompany RepresentativesLeslie Trigg - Chair, Chief Executive OfficerNabeel Ahmed - Chief…
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Recorded net revenue of $32.0 million in the fourth quarter, a 15.3% increase compared to $27.8 million in the third quarter, and a 14.0% increase compared to $28.2 milli
Outset Medical (NASDAQ: OM ) is set to give its latest quarterly earnings report on Monday, 2023-02-13. Here''s what investors need to know before the announcement. Analysts estimate that Outset Medical will report an earnings per share (EPS) of $-0.83. Outset Medical bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
